Skip to main content
. 2022 Apr 11;19(8):4578. doi: 10.3390/ijerph19084578

Figure 3.

Figure 3

Availability of three targeted anticancer drugs: (a) Rituximab; (b) Trastuzumab; (c) Recombinant human endostatin.